Brieka – Medicinal Product Register of Latvia

Pregabalinum

Search by the name of the active substance

Return to the results

Medicinal product name

Brieka 150 mg hard capsules

Pharmaceutical form

Capsule, hard

Strength

150 mg

Information from the MAH on shortages

No information on expected shortages

Availability of medicinal product

Product No.	Package size	Wholesalers' stock state
15-0191-04	N56	Is available

Legal status

Rx Prescription (Pr.III)

Package leaflet

17-04-2024

Summary of product characteristics

17-04-2024

ATC code

N02BF02 – Analgesics

Information for Marketing authorisation holders

View

Product information leaflet and summary of product characteristics in MS Word format.

Package leaflet	17-04-2024
Summary of product characteristics	17-04-2024

Medicinal products (6)

Display only medicinal products with a declared price

Display only medicinal products available in wholesalers' stock

Availability of medicinal product	Wholesalers	Package size, content	Primary packaging	Maximum admissible pharmacy price (€ incl. VAT)	Product No.	Labelling
Not available (according to the information provided by wholesalers)	currently no information on availability from any wholesaler	N100 (150 mg)	HDPE bottle		15-0191-01	Labelling text Jun 21, 2023 Labelling text Jun 21, 2023
Not available (according to the information provided by wholesalers)	currently no information on availability from any wholesaler	N14 (150 mg)	PVC/Al blister		15-0191-02	Labelling text Jun 21, 2023 Labelling text Jun 21, 2023
Not available (according to the information provided by wholesalers)	currently no information on availability from any wholesaler	N30 (150 mg)	PVC/Al blister		15-0191-03	Labelling text Jun 21, 2023 Labelling text Jun 21, 2023
Is available (according to the information provided by wholesalers) (102 containers)	Tamro, Recipe Plus	N56 (150 mg)	PVC/Al blister	€ 39.21	15-0191-04	Labelling text Jun 21, 2023 Labelling text Jun 21, 2023
Not available (according to the information provided by wholesalers)	currently no information on availability from any wholesaler	N60 (150 mg)	PVC/Al blister		15-0191-05	Labelling text Jun 21, 2023 Labelling text Jun 21, 2023
Not available (according to the information provided by wholesalers)	currently no information on availability from any wholesaler	N100 (150 mg)	PVC/Al blister		15-0191-06	Labelling text Jun 21, 2023 Labelling text Jun 21, 2023

Registration information

Marketing authorisation No.	15-0191
Date of authorisation	Sep 9, 2015
Marketing authorisation holder, country	Teva B.V., Netherlands

Return to the results

Icon explanation

– Medicine is available
– Medicine is not available
– Distribution permitted for a limited time span
– Without a prescription
– Prescription medicine

– Medicine is listed on the Latvian National Health Service (NHS) list of state reimbursed medicines. (source of the information – the NHS)
– Reference medicine on the NHS List of state reimbursed medicines
– Lowest cost medicine within its therapeutic effectiveness class in cases where no reference medicine is available
- – Next lowest cost medicine after or (in ascending order)

Class A A (green): Suitable for the older persons. The medicinal substance can be used as in younger patients. Changes due to aging do not affect the dose or frequency of administration, and the adverse reaction profile is not different from that of younger patients.

Class B B (grey): There is little research evidence, practical experience or efficacy in older persons.

Class C C (yellow): Suitable for older persons, with specific cautions. The medicinal substance can be used by older persons, but the dose might either have to be reduced, or the frequency of administration decreased due to mild or moderate renal insufficiency or a significant risk of interactions or adverse reactions.

Class D D (red): Avoid use in older persons. Use is possible only in exceptional cases or on a one-off basis. Changes due to aging predispose older persons to adverse or dangerous reactions to the drug. The risk of adverse reactions typically exceeds the benefits.

Meds75+ data source is Finnish Medicines Agency Fimea (licensed under CC BY 4.0).
Data updated on Apr 23, 2024.